v3.26.3
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2026
Dec. 31, 2025
Accounts receivable, net of allowances $ 4,378 $ 2,755
Related party accounts receivable [1] 380,744 311,170
Related party deferred revenue [2] $ 85,931 $ 92,673
Treasury stock common shares 203,431 183,229
Redeemable Convertible Preferred Stock [Member]    
Temporary equity par or stated value per share $ 0.0001 $ 0.0001
Temporary equity shares authorized 20,000,000 20,000,000
Temporary equity shares outstanding 0 0
Common Class A [Member]    
Common stock par or stated value per share $ 0.0001 $ 0.0001
Common stock shares authorized 1,000,000,000 1,000,000,000
Common stock shares outstanding 177,182,062 173,235,428
Common Class B [Member]    
Common stock par or stated value per share $ 0.0001 $ 0.0001
Common stock shares authorized 5,500,000 5,500,000
Common stock shares outstanding 5,043,789 5,043,789
Related Party [Member]    
Related party deferred revenue $ 100 $ 3,900
Pathos AI [Member]    
Related party accounts receivable 12,092 6,428
Related party deferred revenue 103 3,938
S B Tempus Corp [Member]    
Related party accounts receivable 318 173
Related party deferred revenue $ 0 $ 6,235
[1] Includes related party accounts receivable from Pathos AI, Inc. of $12,092 and $6,428 as of September 30, 2026 and December 31, 2025, respectively. Refer to Note 16, Related Parties. Also includes related party accounts receivable from SB Tempus Corp. of $318 and $173 as of September 30, 2026 and December 31, 2025, respectively. Refer to Note 7, Joint Venture.
[2] Includes related party deferred revenue from Pathos AI, Inc. of $103 and $3,938 as of September 30, 2026 and December 31, 2025, respectively. Refer to Note 16, Related Parties. Also includes related party deferred revenue from SB Tempus Corp. of $0 and $6,235 as of September 30, 2026 and December 31, 2025, respectively. Refer to Note 7, Joint Venture.